Literature DB >> 29194473

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.

C Buske1, M Hutchings2, M Ladetto3, V Goede4, U Mey5, P Soubeyran6, M Spina7, R Stauder8, M Trněný9, U Wedding10, P Fields11.   

Abstract

The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use, and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically-relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were presented to the entire panel and a consensus was reached. This consensus, which was further developed in continuous post-meeting discussions, formed the basis of three manuscripts, each covering one of the three key areas identified. This manuscript presents the consensus recommendations regarding the clinical management of elderly patients diagnosed with malignant lymphoma. Four clinically-relevant topics identified by the panel were: 1) how to define patient fitness, 2) assessing quality of life, 3) diagnostic work-up and 4) clinical management of elderly patients with lymphoma. Each of these key topics is addressed in the context of five different lymphoma entities, namely: CLL, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and diffuse large B-cell lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript.

Entities:  

Mesh:

Year:  2018        PMID: 29194473     DOI: 10.1093/annonc/mdx413

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  16 in total

1.  Diagnostic test of dynamic computed tomography in early gastrointestinal lymphoma and precancerous lesions.

Authors:  Jingcong Chen; Yu Zhong; Xiangling Zeng; Chunyu Huang; Bowen Lan
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

2.  High total metabolic tumor volume at baseline predicts survival independent of response to therapy.

Authors:  Laetitia Vercellino; Anne-Segolene Cottereau; Olivier Casasnovas; Hervé Tilly; Pierre Feugier; Loic Chartier; Christophe Fruchart; Louise Roulin; Lucie Oberic; Gian Matteo Pica; Vincent Ribrag; Julie Abraham; Marc Simon; Hugo Gonzalez; Reda Bouabdallah; Olivier Fitoussi; Catherine Sebban; Armando López-Guillermo; Laurence Sanhes; Franck Morschhauser; Judith Trotman; Bernadette Corront; Bachra Choufi; Sylvia Snauwaert; Pascal Godmer; Josette Briere; Gilles Salles; Philippe Gaulard; Michel Meignan; Catherine Thieblemont
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

3.  Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study.

Authors:  Kelly M Trevino; Peter Martin; Zhengming Chen; John P Leonard
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-08-12

4.  The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent.

Authors:  Florian Kocher; Michael Mian; Andreas Seeber; Michael Fiegl; Reinhard Stauder
Journal:  J Clin Med       Date:  2020-04-02       Impact factor: 4.241

5.  Fatigue at baseline is associated with geriatric impairments and represents an adverse prognostic factor in older patients with a hematological malignancy.

Authors:  F Hofer; K A Koinig; L Nagl; B Borjan; R Stauder
Journal:  Ann Hematol       Date:  2018-07-28       Impact factor: 3.673

6.  Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Authors:  Antonio Cuneo; George Follows; Gian Matteo Rigolin; Alfonso Piciocchi; Alessandra Tedeschi; Livio Trentin; Angeles Medina Perez; Marta Coscia; Luca Laurenti; Gerardo Musuraca; Lucia Farina; Alfredo Rivas Delgado; Ester Maria Orlandi; Piero Galieni; Francesca Romana Mauro; Carlo Visco; Angela Amendola; Atto Billio; Roberto Marasca; Annalisa Chiarenza; Vittorio Meneghini; Fiorella Ilariucci; Monia Marchetti; Stefano Molica; Francesca Re; Gianluca Gaidano; Marcos Gonzalez; Francesco Forconi; Stefania Ciolli; Agostino Cortelezzi; Marco Montillo; Lukas Smolej; Anna Schuh; Toby A Eyre; Ben Kennedy; Kris M Bowles; Marco Vignetti; Javier de la Serna; Carol Moreno; Robin Foà; Paolo Ghia
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

Review 7.  How I treat elderly patients with plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Despoina Fotiou; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Evangelos Terpos; Meletios Athanasios Dimopoulos
Journal:  Aging (Albany NY)       Date:  2018-12-18       Impact factor: 5.682

8.  Extensive colonic pneumatosis in a patient on adjuvant chemotherapy after right colectomy for primary terminal ileum lymphoma: A decision-making process between surgical and non-surgical management.

Authors:  M Kirmanidis; K A Boulas; A Paraskeva; I Kariotis; N Barettas; S Kariotis; Ch Keskinis; A Hatzigeorgiadis
Journal:  Int J Surg Case Rep       Date:  2018-10-09

Review 9.  State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019.

Authors:  Richard Lemal; Olivier Tournilhac
Journal:  J Immunother Cancer       Date:  2019-08-01       Impact factor: 13.751

10.  Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas.

Authors:  Prokop Vodicka; Lenka Krskova; Igor Odintsov; Ludmila Krizova; Eva Sedlackova; Jan Schutzner; Josef Zamecnik
Journal:  Oncol Lett       Date:  2020-01-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.